Epilepsy Drugs Market By Seizure Type (Focal seizures, Generalized seizures, Non-epileptic seizures), By Drugs Generation (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Epilepsy Drugs Market

The Epilepsy Drugs Market is likely to experience a significant growth rate of 3.5% from 2023-2032 owing to increase in demand for epilepsy drugs from pharmaceuticals sector –

Epilepsy drugs are used to manage and control seizures in individuals with epilepsy. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures, which are caused by abnormal electrical activity in the brain. These drugs work by suppressing or reducing the excessive and abnormal electrical activity in the brain to prevent or reduce the frequency and severity of seizures.

Key factors driving the growth of the epilepsy drugs market include rise in prevalence of epilepsy, rise in geriatric population need for more effective and safer treatment options for epilepsy. Epilepsy is a chronic neurological disorder that affects millions of people worldwide. While there are several treatment options available, they are not always effective for everyone and are associated with significant side effects. Thus, there is a significant demand for new and improved epilepsy drugs that can provide better outcomes with fewer side effects this led to an increase in demand for epilepsy drugs and further drive the market growth. In addition, epilepsy is not limited to any age group and its prevalence tends to increase with age. Therefore, rise in geriatric population increases the demand for epilepsy drugs, as elderly individuals with epilepsy require ongoing treatment to manage their condition which support the market growth.

Furthermore, rise in awareness about importance of early diagnosis and treatment for epilepsy led to a increase in the demand for drugs that can treat this disorder. This is driving the growth of the epilepsy drugs market. For instance, The National Health Service (NHS) in the UK developed an Epilepsy Action Plan, which aims to improve the quality of care for people with epilepsy. Thus, rise in prevalence of epilepsy, rise in geriatric population, and increase in awareness regarding epilepsy and its treatment are the factors that driving the growth of the market.  

The market also offers growth opportunities to the key players in the market. Advances in technology and research such as improved efficacy and tolerability of existing drugs, developing personalized therapies, and introducing innovative drug delivery systems which creates lucrative opportunity to the market growth.  Rise in technologies such as high-throughput screening and computer modeling have revolutionized the drug discovery and development process, enabling researchers to identify potential drug candidates more quickly and efficiently. In addition, advancements in technology and research led to the development of new epilepsy drugs with improved efficacy, more effective at controlling seizures which is driving the demand for antiepileptic drugs and is expected to provide lucrative opportunities for the growth of the market during the forecast period.  

The epilepsy drugs market is segmented into seizure type, drug generation, distribution channel, and region. On the basis of drug type, the market is categorized into focal seizures, generalized seizures, and non-epileptic seizures. On the basis of drugs generation, it is segmented into first generation drugs, second generation drugs, and third generation drugs. On the basis of distribution channel, it is divided into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include Novartis AG, GlaxoSmithKline plc, Sanofi, UCB S.A., Abbott Laboratories, Bausch Health Companies, Inc, Viatris Inc., Johnson & Johnson, Sumitomo Pharma Co., Ltd, and H. Lundbeck A/S. The players in the market have been actively engaged in the adoption various strategy such as product approval to remain competitive and gain advantage over the competitors in the market. For instance, in November 2020, UCB S.A., a global pharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved VIMPAT (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients who are four years of age and older.

Key Market Insights (Updated)

• By seizure type, the focal seizures segment was the largest revenue contributor to the market and is estimated to reach $5,580.64 million by 2032. However, the generalized segment is expected to be the fastest-growing segment with a CAGR of 3.8% during the forecast period.  

• By drugs generation, the second-generation drugs segment dominated the global market. However, the third-generation drugs segment is expected to be the fastest-growing segment with a CAGR of 5.4% during the forecast period.

• Based on distribution channel, the drug stores and retail pharmacies segment was the largest revenue contributor to the market in 2022. However, the online providers segment is expected to be the fastest-growing segment with a CAGR of 6.2% during the forecast period.  

• Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The global epilepsy drugs market valued for $6,945.20 million in 2022 and is estimated to reach $9,802.45 million by 2032, exhibiting a CAGR of 3.5% from 2023 to 2032. 

Epilepsy is a neurological disorder that affects the brain and causes recurrent seizures. Seizures are sudden, abnormal electrical discharges in the brain that can cause a wide range of symptoms depending on the area of the brain affected. Symptoms of epilepsy include sudden and uncontrolled movements or convulsions, loss of consciousness, altered sensations, confusion, memory loss, and emotional changes. The frequency, duration, and severity of seizures vary among individuals with epilepsy. Epilepsy has multiple causes, including genetic factors, brain injuries, infections, brain tumors, stroke, developmental disorders, and other underlying neurological conditions.  

The primary goal of treatment for epilepsy is to control or reduce the frequency and severity of seizures and minimize the side effects of medications. The antiepileptic drugs (AEDs) work by suppressing abnormal electrical activity in the brain. Epilepsy drugs, also known as antiepileptic drugs (AEDs) or antiseizure medications, are a class of medications used to manage and treat epilepsy. Epilepsy drugs work by reducing or preventing the occurrence of seizures, which are abnormal electrical activities in the brain.  

The epilepsy drugs market growth is driven by factors such as the increase in prevalence of epilepsy, rise in awareness about epilepsy condition, and surge in geriatric population as they have higher risk of developing epilepsy. For instance, according to the World Health Organization (WHO), in February 2023, around 50 million people worldwide had epilepsy, making it one of the most common neurological diseases globally. In addition, from the same source, in high-income countries, there is an estimated 49 per 100,000 patients diagnosed with epilepsy each year. Thus, increase in prevalence of epilepsy condition and high burden of epilepsy are expected to foster the demand for medications to manage the seizures and drive the market growth.  

Moreover, rise in demand for generic antiepileptic drugs has influenced the market growth. For instance, generic version of antiepileptics drugs such as levetiracetam are less expensive, more affordable, and accessible to wider population, thereby driving the market growth. Furthermore, rise in awareness about early diagnosis and treatment for epilepsy, which help to control seizures, further increases the demand for epilepsy drugs and drive growth of the market. 

However, epilepsy drugs have potential adverse effects and safety concerns that hinder the market growth. Safety concerns related to side effects, drug interactions, and long-term safety profiles may impact the utilization of epilepsy drugs, especially if they are associated with serious risks. Safety concerns result in regulatory warnings or restrictions, decreased patient adherence, and reduced physician confidence in prescribing certain epilepsy drugs, which negatively affect the market growth. On the contrary,  high growth potential in emerging countries owing to rise in awareness about early diagnosis and treatment offers lucrative opportunities to key players of the epilepsy drugs market. 

The epilepsy drugs market is segmented on the basis of seizure type, drug generation, distribution channel, and region. By seizure type, the market is segregated into focal seizures, generalized seizures, and non-epileptic seizures. By drug generation, the market is categorized into first generation drugs, second generation drugs, and third generation drugs. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major key players that operate in the epilepsy drugs market are Novartis AG, GlaxoSmithKline plc, Sanofi, UCB S.A., Abbott Laboratories, Bausch Health Companies, Inc, Viatris Inc., Johnson & Johnson, Sumitomo Pharma Co., Ltd, and H. Lundbeck A/S. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio. For instance, in November 2020, UCB S.A., a global pharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved VIMPAT (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients who are four years of age and older. 

increase in demand for epilepsy drugs and rise in awareness about importance of early diagnosis and treatment is expected to offer profitable opportunities for the expansion of the market. However, side effects of epilepsy drugs such as drowsiness, fatigue, and gastrointestinal symptoms hinder the market growth. 

The surge in incidences of epilepsy drives the demand for antiepileptic drugs and supports the market growth. Moreover, rise in awareness about increase in number of generic drug manufactures and increase in ageing population, as they are more prone to develop epilepsy, are some factors that further boost market growth. 

Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to the rise in prevalence of epilepsy along with surge in geriatric population and presence of major key players in the region. However, Asia-Pacific is anticipated to witness notable growth owing to rise in healthcare awareness and increase in incidences of epilepsy. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epilepsy drugs market analysis from 2022 to 2032 to identify the prevailing epilepsy drugs market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the epilepsy drugs market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global epilepsy drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Viatris Inc

Scope of Epilepsy Drugs Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of epilepsy

3.4.1.2. Need for more effective and safer treatment options for epilepsy

3.4.1.3. Increase in geriatric population

3.4.2. Restraints

3.4.2.1. Side effects of epilepsy drugs

3.4.3. Opportunities

3.4.3.1. Advances in technology and research

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Focal seizures

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Generalized seizures

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Non-epileptic seizures

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. First Generation Drugs

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Second Generation Drugs

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Third Generation Drugs

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug Stores and Retail Pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online Providers

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Seizure Type

7.2.3. Market size and forecast, by Drugs Generation

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Seizure Type

7.2.5.1.3. Market size and forecast, by Drugs Generation

7.2.5.1.4. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Seizure Type

7.2.5.2.3. Market size and forecast, by Drugs Generation

7.2.5.2.4. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Seizure Type

7.2.5.3.3. Market size and forecast, by Drugs Generation

7.2.5.3.4. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Seizure Type

7.3.3. Market size and forecast, by Drugs Generation

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Seizure Type

7.3.5.1.3. Market size and forecast, by Drugs Generation

7.3.5.1.4. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Seizure Type

7.3.5.2.3. Market size and forecast, by Drugs Generation

7.3.5.2.4. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Seizure Type

7.3.5.3.3. Market size and forecast, by Drugs Generation

7.3.5.3.4. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Seizure Type

7.3.5.4.3. Market size and forecast, by Drugs Generation

7.3.5.4.4. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Seizure Type

7.3.5.5.3. Market size and forecast, by Drugs Generation

7.3.5.5.4. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Seizure Type

7.3.5.6.3. Market size and forecast, by Drugs Generation

7.3.5.6.4. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Seizure Type

7.4.3. Market size and forecast, by Drugs Generation

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Seizure Type

7.4.5.1.3. Market size and forecast, by Drugs Generation

7.4.5.1.4. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Seizure Type

7.4.5.2.3. Market size and forecast, by Drugs Generation

7.4.5.2.4. Market size and forecast, by Distribution Channel

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Seizure Type

7.4.5.3.3. Market size and forecast, by Drugs Generation

7.4.5.3.4. Market size and forecast, by Distribution Channel

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Seizure Type

7.4.5.4.3. Market size and forecast, by Drugs Generation

7.4.5.4.4. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Seizure Type

7.4.5.5.3. Market size and forecast, by Drugs Generation

7.4.5.5.4. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Seizure Type

7.4.5.6.3. Market size and forecast, by Drugs Generation

7.4.5.6.4. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Seizure Type

7.5.3. Market size and forecast, by Drugs Generation

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Seizure Type

7.5.5.1.3. Market size and forecast, by Drugs Generation

7.5.5.1.4. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Seizure Type

7.5.5.2.3. Market size and forecast, by Drugs Generation

7.5.5.2.4. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Seizure Type

7.5.5.3.3. Market size and forecast, by Drugs Generation

7.5.5.3.4. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Seizure Type

7.5.5.4.3. Market size and forecast, by Drugs Generation

7.5.5.4.4. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Novartis AG

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. GlaxoSmithKline plc

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Sanofi

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. UCB S.A.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Abbott Laboratories

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Bausch Health Companies, Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.7. H. Lundbeck A/S

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Viatris Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Sumitomo Pharma Co., Ltd

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Johnson & Johnson

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 02. EPILEPSY DRUGS MARKET FOR FOCAL SEIZURES, BY REGION, 2022-2032 ($MILLION)

TABLE 03. EPILEPSY DRUGS MARKET FOR GENERALIZED SEIZURES, BY REGION, 2022-2032 ($MILLION)

TABLE 04. EPILEPSY DRUGS MARKET FOR NON-EPILEPTIC SEIZURES, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 06. EPILEPSY DRUGS MARKET FOR FIRST GENERATION DRUGS, BY REGION, 2022-2032 ($MILLION)

TABLE 07. EPILEPSY DRUGS MARKET FOR SECOND GENERATION DRUGS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. EPILEPSY DRUGS MARKET FOR THIRD GENERATION DRUGS, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 10. EPILEPSY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 11. EPILEPSY DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 12. EPILEPSY DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. EPILEPSY DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA EPILEPSY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 18. U.S. EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 19. U.S. EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 20. U.S. EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 21. CANADA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 22. CANADA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 23. CANADA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 24. MEXICO EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 25. MEXICO EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 26. MEXICO EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 27. EUROPE EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 28. EUROPE EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 29. EUROPE EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 30. EUROPE EPILEPSY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 31. GERMANY EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 32. GERMANY EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 33. GERMANY EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 34. FRANCE EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 35. FRANCE EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 36. FRANCE EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 37. UK EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 38. UK EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 39. UK EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 40. ITALY EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 41. ITALY EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 42. ITALY EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 43. SPAIN EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 44. SPAIN EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 45. SPAIN EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 46. REST OF EUROPE EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC EPILEPSY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 53. JAPAN EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 54. JAPAN EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 55. JAPAN EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 56. CHINA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 57. CHINA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 58. CHINA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 59. INDIA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 60. INDIA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 61. INDIA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 62. AUSTRALIA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 63. AUSTRALIA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 64. AUSTRALIA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 65. SOUTH KOREA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 71. LAMEA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 72. LAMEA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 73. LAMEA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 74. LAMEA EPILEPSY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 75. BRAZIL EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 76. BRAZIL EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 77. BRAZIL EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 78. SAUDI ARABIA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 81. SOUTH AFRICA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 84. REST OF LAMEA EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 87. NOVARTIS AG: KEY EXECUTIVES

TABLE 88. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 89. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 90. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 91. GLAXOSMITHKLINE PLC: KEY EXECUTIVES

TABLE 92. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS

TABLE 94. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 95. SANOFI: KEY EXECUTIVES

TABLE 96. SANOFI: COMPANY SNAPSHOT

TABLE 97. SANOFI: PRODUCT SEGMENTS

TABLE 98. SANOFI: PRODUCT PORTFOLIO

TABLE 99. UCB S.A.: KEY EXECUTIVES

TABLE 100. UCB S.A.: COMPANY SNAPSHOT

TABLE 101. UCB S.A.: PRODUCT SEGMENTS

TABLE 102. UCB S.A.: PRODUCT PORTFOLIO

TABLE 103. UCB S.A.: KEY STRATERGIES

TABLE 104. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 105. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 106. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 107. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 108. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES

TABLE 109. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 110. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS

TABLE 111. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 112. H. LUNDBECK A/S: KEY EXECUTIVES

TABLE 113. H. LUNDBECK A/S: COMPANY SNAPSHOT

TABLE 114. H. LUNDBECK A/S: PRODUCT SEGMENTS

TABLE 115. H. LUNDBECK A/S: PRODUCT PORTFOLIO

TABLE 116. VIATRIS INC.: KEY EXECUTIVES

TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT

TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS

TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO

TABLE 120. SUMITOMO PHARMA CO., LTD: KEY EXECUTIVES

TABLE 121. SUMITOMO PHARMA CO., LTD: COMPANY SNAPSHOT

TABLE 122. SUMITOMO PHARMA CO., LTD: PRODUCT SEGMENTS

TABLE 123. SUMITOMO PHARMA CO., LTD: PRODUCT PORTFOLIO

TABLE 124. JOHNSON & JOHNSON: KEY EXECUTIVES

TABLE 125. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 126. JOHNSON & JOHNSON: PRODUCT SEGMENTS

TABLE 127. JOHNSON & JOHNSON: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. EPILEPSY DRUGS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF EPILEPSY DRUGS MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN EPILEPSY DRUGS MARKET (2023-2032)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW BARGAINING POWER OF BUYERS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW THREAT OF NEW ENTRANTS

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALEPILEPSY DRUGS MARKET

FIGURE 10. EPILEPSY DRUGS MARKET, BY SEIZURE TYPE, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR FOCAL SEIZURES, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR GENERALIZED SEIZURES, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR NON-EPILEPTIC SEIZURES, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. EPILEPSY DRUGS MARKET, BY DRUGS GENERATION, 2022(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR FIRST GENERATION DRUGS, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR SECOND GENERATION DRUGS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR THIRD GENERATION DRUGS, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. EPILEPSY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF EPILEPSY DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. EPILEPSY DRUGS MARKET BY REGION, 2022

FIGURE 23. U.S. EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 24. CANADA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 25. MEXICO EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 26. GERMANY EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 27. FRANCE EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 28. UK EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 29. ITALY EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 30. SPAIN EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 31. REST OF EUROPE EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 32. JAPAN EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 33. CHINA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 34. INDIA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 35. AUSTRALIA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 36. SOUTH KOREA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 37. REST OF ASIA-PACIFIC EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 38. BRAZIL EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 39. SAUDI ARABIA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 40. SOUTH AFRICA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 41. REST OF LAMEA EPILEPSY DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46. COMPETITIVE DASHBOARD

FIGURE 47. COMPETITIVE HEATMAP: EPILEPSY DRUGS MARKET

FIGURE 48. TOP PLAYER POSITIONING, 2022

FIGURE 49. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 50. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 51. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 52. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)

FIGURE 53. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. SANOFI: NET SALES, 2020-2022 ($MILLION)

FIGURE 56. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 57. SANOFI: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 58. UCB S.A.: NET SALES, 2020-2022 ($MILLION)

FIGURE 59. UCB S.A.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. BAUSCH HEALTH COMPANIES, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 64. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 65. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 66. H. LUNDBECK A/S: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 67. H. LUNDBECK A/S: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 68. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 69. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 70. SUMITOMO PHARMA CO., LTD: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 71. SUMITOMO PHARMA CO., LTD: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 72. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)

FIGURE 73. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 74. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%